BIIB vs NKTR · P/E 21, rev $9.89B vs rev $21.0M
Biogen Inc (BIIB) versus Nektar Therapeutics (NKTR) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported NKTR revenue for 2026-06-30 was $21.0M. Net income was -$85.5M. Revenue was up 93.3% from 2026-03-31 to 2026-06-30. NKTR currently screens at market cap $307.2M.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. NKTR currently screens at market cap $307.2M.
Not investment advice. Open the BIIB and NKTR stock pages for the full models.
Not investment advice.